Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDBarinthus Biotherapeutics plc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 2 | -$0.40 | -$0.30 | -$0.36 |
| Q2 2025 | 1 | -$0.36 | -$0.36 | -$0.36 |
| Q3 2025 | 1 | -$0.36 | -$0.36 | -$0.36 |
| Q4 2025 | 1 | -$0.37 | -$0.37 | -$0.37 |
| Q1 2026 | 1 | -$0.41 | -$0.41 | -$0.41 |
| Q2 2026 | 1 | -$0.40 | -$0.40 | -$0.40 |
| Q3 2026 | 1 | -$0.45 | -$0.45 | -$0.45 |
| Q4 2026 | 1 | -$0.44 | -$0.44 | -$0.44 |
| Q1 2027 | 1 | -$0.48 | -$0.48 | -$0.48 |
| Q2 2027 | 1 | -$0.48 | -$0.48 | -$0.48 |
| Q3 2027 | 1 | -$0.52 | -$0.52 | -$0.52 |
| Q4 2027 | 1 | -$0.51 | -$0.51 | -$0.51 |
Barinthus Biotherapeutics plc Earnings Date And Information
Barinthus Biotherapeutics plc last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.21 earnings per share for the quarter, topping analysts' consensus estimates of $-0.45 by $0.24. The company had revenue of 14.97 M for the quarter and had revenue of 802,000 for the year. Barinthus Biotherapeutics plc has generated $-2 earnings per share over the last year ($-1.91 diluted earnings per share) and currently has a price-to-earnings ratio of -0.73. Barinthus Biotherapeutics plc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 18th, 2025 based on prior year's report dates.
Barinthus Biotherapeutics plc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$0.45 | -$0.21 | 0.24 | $166,667 | $14.97 M |
| 08/08/2024 | Q2 2024 | -$0.42 | -$0.43 | -0.01 | $166,667 | $0 |
| 05/13/2024 | Q1 2024 | -$0.64 | -$0.40 | 0.24 | N/A | $0 |
| 03/20/2024 | Q4 2023 | -$0.55 | -$0.45 | 0.1 | N/A | $5.37 M |
| 09/29/2023 | Q3 2023 | N/A | -$0.37 | N/A | $250,000 | $0 |
| 06/29/2023 | Q2 2023 | N/A | -$0.62 | N/A | $704,250 | $334,000 |
| 03/30/2023 | Q1 2023 | N/A | -$0.48 | N/A | N/A | $468,000 |
| 12/30/2022 | Q4 2022 | N/A | -$0.56 | N/A | N/A | $6.46 M |
| 09/29/2022 | Q3 2022 | N/A | $0.22 | N/A | $7.80 M | $6.17 M |
| 06/29/2022 | Q2 2022 | N/A | $0.42 | N/A | $3.71 M | $17.06 M |
| 03/30/2022 | Q1 2022 | N/A | $0.07 | N/A | N/A | $15.02 M |
| 12/30/2021 | Q4 2021 | N/A | $0.00 | N/A | N/A | $-1,000 |
| 09/29/2021 | Q3 2021 | N/A | -$0.13 | N/A | $100,000 | $19,000 |
| 06/29/2021 | Q2 2021 | N/A | -$0.64 | N/A | $33,333 | $35,000 |
| 03/30/2021 | Q1 2021 | N/A | -$0.45 | N/A | N/A | $215,000 |
| 12/30/2020 | Q4 2020 | N/A | $0.00 | N/A | N/A | $353,257 |
| 09/29/2020 | Q3 2020 | N/A | $3.32 | N/A | N/A | $3.25 M |
| 06/29/2020 | Q2 2020 | N/A | -$75.31 | N/A | N/A | $511,000 |
| 03/30/2020 | Q1 2020 | N/A | -$80.20 | N/A | N/A | $705,000 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Barinthus Biotherapeutics plc Earnings: FAQ's
Barinthus Biotherapeutics plc has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 18th, 2025 based offlast year's report dates.
In the previous quarter, Barinthus Biotherapeutics plc (:BRNS) reported $-0.21 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.45 by $0.24.
The conference call for Barinthus Biotherapeutics plc's latest earnings report can be listened to online.
The conference call transcript for Barinthus Biotherapeutics plc's latest earnings report can be read online.
Barinthus Biotherapeutics plc (:BRNS) has a recorded annual revenue of $802,000.
Barinthus Biotherapeutics plc (:BRNS) has a recorded net income of $-73,347,000.Barinthus Biotherapeutics plc has generated $-1.91 earnings per share over the last four quarters.
Barinthus Biotherapeutics plc (:BRNS) has a price-to-earnings ratio of -0.73 and price/earnings-to-growth ratio is -0.08.